بينما نتطلع إلى المستقبل، نقود مسيرة البناء بتقنيات الأبنية الذكية وأساليب البناء الأخضر.
The WHO Expert Committee recommended the inclusion of ravidasvir on the core list of the EML as a therapeutic alternative under the square box listing for pangenotypic direct-acting antivirals for the treatment of chronic hepatitis C virus infection in adults. Ravidasvir is pangenotypic when used in combination with sofosbuvir. The recommendation was made based on evidence of effectiveness and safety, similar to that seen with other pangenotypic direct-acting antiviral regimens.
